📊 PRTA Key Takeaways
Is Prothena Corp. Public Ltd. Co (PRTA) a Good Investment?
Prothena faces severe fundamental deterioration with 31.5% revenue decline and near-complete earnings collapse (99.6% YoY), indicating critical business model failure in its pharmaceutical operations likely from pipeline shortfalls or product losses. While the fortress balance sheet ($329.5M cash, zero debt) delays insolvency, absent credible turnaround evidence or pipeline catalysts, the company will face accelerating shareholder value destruction.
Prothena Corp. Public Ltd. Co Key Strengths (PRTA)
- Fortress balance sheet with $329.5M cash and zero debt provides 2+ year runway for turnaround attempts
- Positive free cash flow of $28.8M despite revenue collapse demonstrates operational resilience
- Operating margin of 58.8% suggests core profitable business segments remain viable
PRTA Stock Risks: Prothena Corp. Public Ltd. Co Investment Risks
- Catastrophic 31.5% revenue decline indicates loss of major products, patents, or market exclusivity in pharmaceutical company
- Net income collapse of 99.6% represents business model deterioration, not temporary cyclical weakness
- Elevated insider Form 4 activity (8 filings) suggests management uncertainty or credibility issues regarding turnaround path
- Continued revenue erosion will eventually exceed cash burn capacity despite current balance sheet strength
- As biotech company, pipeline risk is existential; no visible evidence of value-accretive assets or clinical success
Key Metrics to Watch
- Quarterly revenue trends and YoY rate of decline stabilization
- Clinical trial progress and regulatory approvals for pipeline programs
- Operating cash flow sustainability and cash burn rate as percentage of reserves
- Management changes, strategic partnerships, or capital deployment announcements
- Cash runway estimate based on current burn rate
Prothena Corp. Public Ltd. Co (PRTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 56.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 10.43x current ratio provides a solid financial cushion.
PRTA Profit Margin, ROE & Profitability Analysis
PRTA vs Healthcare Sector: How Prothena Corp. Public Ltd. Co Compares
How Prothena Corp. Public Ltd. Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prothena Corp. Public Ltd. Co Stock Overvalued? PRTA Valuation Analysis 2026
Based on fundamental analysis, Prothena Corp. Public Ltd. Co appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prothena Corp. Public Ltd. Co Balance Sheet: PRTA Debt, Cash & Liquidity
PRTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prothena Corp. Public Ltd. Co's revenue has declined by 33% over the 5-year period, indicating business contraction. The most recent EPS of $-2.76 indicates the company is currently unprofitable.
PRTA Revenue Growth, EPS Growth & YoY Performance
PRTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8M | $32.7M | $0.60 |
| Q3 2025 | $970.0K | -$36.5M | $-0.68 |
| Q2 2025 | $4.4M | -$5.4M | $-0.10 |
| Q1 2025 | $50.0K | -$60.2M | $-1.12 |
| Q3 2024 | $970.0K | $21.9M | $0.38 |
| Q2 2024 | $4.0M | -$5.4M | $-0.10 |
| Q1 2024 | $50.0K | -$46.9M | $-0.89 |
| Q3 2023 | $1.5M | $21.9M | $0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prothena Corp. Public Ltd. Co Dividends, Buybacks & Capital Allocation
PRTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prothena Corp. Public Ltd. Co (CIK: 0001559053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRTA
What is the AI rating for PRTA?
Prothena Corp. Public Ltd. Co (PRTA) has an AI grade of C with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRTA's key strengths?
Claude: Fortress balance sheet with $329.5M cash and zero debt provides 2+ year runway for turnaround attempts. Positive free cash flow of $28.8M despite revenue collapse demonstrates operational resilience.
What are the risks of investing in PRTA?
Claude: Catastrophic 31.5% revenue decline indicates loss of major products, patents, or market exclusivity in pharmaceutical company. Net income collapse of 99.6% represents business model deterioration, not temporary cyclical weakness.
What is PRTA's revenue and growth?
Prothena Corp. Public Ltd. Co reported revenue of $51.1M.
Does PRTA pay dividends?
Prothena Corp. Public Ltd. Co does not currently pay dividends.
Where can I find PRTA SEC filings?
Official SEC filings for Prothena Corp. Public Ltd. Co (CIK: 0001559053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRTA's EPS?
Prothena Corp. Public Ltd. Co has a diluted EPS of $0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRTA's fundamental grade?
Based on our AI fundamental analysis in May 2026, Prothena Corp. Public Ltd. Co has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRTA stock overvalued or undervalued?
Valuation metrics for PRTA: ROE of 10.5% (sector avg: 15%), net margin of 64.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRTA's AI grade for 2026?
Our dual AI analysis gives Prothena Corp. Public Ltd. Co a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PRTA's free cash flow?
Prothena Corp. Public Ltd. Co's operating cash flow is $28.9M, with capital expenditures of $110.0K. FCF margin is 56.3%.
How does PRTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 64.1% (avg: 12%), ROE 10.5% (avg: 15%), current ratio 10.43 (avg: 2).